Adjuvant anti-PD-1 therapy improves melanoma-specific survival in stage IIIC-IV melanoma patients with high tumor mutation burden and BRAF V600 mutation by Julia Forschner, Julia Huynh, Christopher Schroeder, Sorin Armeanu-Ebinger, Olga Seibel-Kelemen, Axel Gschwind, Irina Bonzheim, Thomas K. Eigentler, Teresa Amaral, Stephan Ossowski, Lukas Flatz, Claus Garbe, Andrea Forschner, Markus Reitmajer

Get full text